Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Supriya Lifescience IPO is a book build issue of ₹700.00 crores. The issue is a combination of fresh issue of 0.73 crore shares aggregating to ₹200.00 crores and offer for sale of 1.82 crore shares aggregating to ₹500.00 crores.
Supriya Lifescience IPO bidding started from Dec 16, 2021 and ended on Dec 20, 2021. The allotment for Supriya Lifescience IPO was finalized on Dec 23, 2021. The shares got listed on BSE, NSE on Dec 28, 2021.
Supriya Lifescience IPO price band is set at ₹274.00 per share . The lot size for an application is 54. The minimum amount of investment required by an retail is ₹14,310 (54 shares). The lot size investment for sNII is 14 lots (756 shares), amounting to ₹2,07,144, and for bNII, it is 68 lots (3,672 shares), amounting to ₹10,06,128.
Axis Capital Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Supriya Lifescience IPO RHP for detailed Information.
| IPO Date | December 16, 2021 to December 20, 2021 |
| Listing Date | December 28, 2021 |
| Face Value | ₹2 per share |
| Issue Price Band | ₹265 to ₹274 per share |
| Issue Price Final | ₹274 per share |
| Lot Size | 54 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 2,55,47,445 shares (aggregating up to ₹700.00 Cr) |
| Fresh Issue | 72,99,270 shares (aggregating up to ₹200.00 Cr) |
| Offer for Sale | 1,82,48,175 shares of ₹2 (aggregating up to ₹500.00 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 7,31,83,530 shares |
| Share Holding Post Issue | 2,55,47,445 shares |
Supriya Lifescience IPO offers total 2,55,47,445 shares. Out of which 1,91,60,585 (75.00%) allocated to QIB, 76,64,234 (30.00%) allocated to QIB, 38,32,116 (15.00%) allocated to NII, 25,54,744 (10.00%) allocated to RII and 1,14,96,351 (45.00%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 1,91,60,585 (75.00%) | NA |
| − Anchor Investor Shares Offered | 1,14,96,351 (45.00%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 76,64,234 (30.00%) | NA |
| NII (HNI) Shares Offered | 38,32,116 (15.00%) | NA |
| Retail Shares Offered | 25,54,744 (10.00%) | 47,310 |
| Total Shares Offered | 2,55,47,445 (100.00%) |
Supriya Lifescience IPO raises ₹315.00 crore from anchor investors. Supriya Lifescience IPO Anchor bid date is December 15, 2021. Supriya Lifescience IPO Anchor Investors list
| Bid Date | December 15, 2021 |
| Shares Offered | 1,14,96,351 |
| Anchor Portion Size (In Cr.) | 315.00 |
| Anchor lock-in period end date for 50% shares (30 Days) | January 22, 2022 |
| Anchor lock-in period end date for remaining shares (90 Days) | March 23, 2022 |
Supriya Lifescience IPO opens on December 16, 2021, and closes on December 20, 2021.
| IPO Open Date | Thu, Dec 16, 2021 |
| IPO Close Date | Mon, Dec 20, 2021 |
| Tentative Allotment | Thu, Dec 23, 2021 |
| Initiation of Refunds | Fri, Dec 24, 2021 |
| Credit of Shares to Demat | Mon, Dec 27, 2021 |
| Tentative Listing Date | Tue, Dec 28, 2021 |
| Cut-off time for UPI mandate confirmation | 5 PM on Mon, Dec 20, 2021 |
Investors can bid for a minimum of 54 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 54 | ₹14,796 |
| Retail (Max) | 13 | 702 | ₹1,92,348 |
| S-HNI (Min) | 14 | 756 | ₹2,07,144 |
| S-HNI (Max) | 67 | 3,618 | ₹9,91,332 |
| B-HNI (Min) | 68 | 3,672 | ₹10,06,128 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. The company is also one of the largest exporters of Salbutamol Sulphate from India in FY 2021 in terms of volume.
In Fiscal 2021, the company's products were exported to 86 countries to 1,296 customers including 346 distributors. The company has API business in Europe, Latin America, Asia, and North America.
Supriya Lifescience has a modern manufacturing facility in Maharashtra spread across 23,806 sq. mts, having a reactor capacity of 547 KL/ day including 7 clean rooms. The company has also acquired a plot of land, admeasuring 12,551 sq. mt, near the present manufacturing facility, to expand its manufacturing infrastructure. The company's manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)- China, Health Canada, in relation to API products being exported to the relevant jurisdictions by the company.
| Particulars | For the year/period ended (₹ in Millions) | ||||
|---|---|---|---|---|---|
| 30-Sep-21 | 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | ||
| Total Assets | 5,041.02 | 4,458.24 | 3,364.01 | 2,530.52 | |
| Total Revenue | 2,300.61 | 3,962.21 | 3,227.13 | 2,858.62 | |
| Profit After Tax | 659.59 | 1,238.28 | 733.74 | 394.24 | |
[Dilip Davda] SLL has been making strides with higher top and bottom lines year after year and exporting over 75% of products to more than 86 countries. Based on financial parameters, the issue is attractively priced leaving something on the table across the board. The issue is worth considering for short to long term rewards. Read detail review...
| Listing Date | December 28, 2021 |
| BSE Script Code | 543434 |
| NSE Symbol | SUPRIYA |
| ISIN | INE07RO01027 |
| Final Issue Price | ₹274 per share |
| BSE Listing Group | B |
Supriya Lifescience Ltd.
207/208, Udyog Bhavan,
Sonawala Road, Goregaon,
East, Mumbai – 400063, Maharashtra, India
Mumbai, Maharashtra
Phone: +91-22-40332727
Email: cs@supriyalifescience.com
Website: https://supriyalifescience.com/
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: supriyalife.ipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Supriya Lifescience IPO is a main-board IPO of 2,55,47,445 equity shares of the face value of ₹2 aggregating up to ₹700.00 Crores. The issue is priced at ₹274 per share. The minimum order quantity is 54.
The IPO opens on December 16, 2021, and closes on December 20, 2021.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Supriya Lifescience IPO using UPI as a payment gateway. Zerodha customers can apply in Supriya Lifescience IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Supriya Lifescience IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Supriya Lifescience IPO opens on December 16, 2021 and closes on December 20, 2021.
Supriya Lifescience IPO lot size is 54, and the minimum amount required for application is ₹14,796.
You can apply in Supriya Lifescience IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Supriya Lifescience IPO will be done on Thursday, December 23, 2021, and the allotted shares will be credited to your demat account by Monday, December 27, 2021. Check the Supriya Lifescience IPO allotment status.
The Supriya Lifescience IPO listing date is on Tuesday, December 28, 2021.
Useful Articles
RHP